CME: Acute Lymphoblastic Leukemia (ALL): Highlights from the 2015 American Society of Hematology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation
ACCREDITATION EXPIRED: May 15, 2018
Activity Description / Statement of Need:
In this online CME self-learning program:
�
Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners.� The 2015 American Society of Hematology Annual Meeting & Exposition (ASH 2015) is no exception.� Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting.�
�
Acute Lymphoblastic Leukemia:
�
Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.� The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.These symptoms include: fatigue, malaise, or palpitations associated with anemia; fever with or without infection due to leukopenia or leukocytosis; and petechiae, and bleeding or bruising of the oral mucosa, skin, or gastrointestinal tract due to thrombocytopenia.� Although the precise etiology of ALL remains unknown, some cases have been associated with: exposure to ionizing, toxic chemicals, herbicides; genetic conditions such as Down�s syndrome, Fanconi syndrome, neurofibromatosis; viruses like human T-lymphotropic viruses 1 and 2 and Epstein-Barr virus.� After clinical suspicion is aroused, diagnostics include: a complete blood count, bone marrow biopsy, and flow cytometry.
�
�
Agenda:
�
|
Faculty member introduction, disclosures |
|
Major findings from ASH 2015, including clinical trial data� relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) |
|
Application: patient cases |
|
Summary, conclusion, and best practice recap |
�
�
�
�
Target Audience:
Hematologist-oncologists, medical oncologists, oncology nurse practitioners, physician assistants who specialize in oncology, and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with ALL.
This program is supported by educational grants from Baxalta and AMGEN.
Release Date: May 15, 2016 -- Expiration Date: May 15, 2018
Faculty: Dan Douer, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
- Additional objectives to be dictated by clinical content
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
�As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
�
Faculty Disclosure:� Dan Douer, MD has received financial compensation from participation at advisory boards and/or research grants from Amgen and Baxalta.
�
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
�
Commercial Support Disclosure: This program is supported by educational grants from Baxalta and AMGEN.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Adult Acute Lymphoblastic Leukemia (ALL) in Adults: 2015 Overview